Navigation Links
WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results

FREMONT, Calif., March 14, 2011 /PRNewswire/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art genomic analysis systems, today reported financial results for the three months and year ended December 31, 2010."We were pleased to see strong revenue growth in 2010 to a total of $2.2 million for the year.   This revenue exceeded our guidance of $1.5 to $2 million for the year," said Alnoor Shivji, Chairman and CEO.   "We have made great progress over the past year to position the SmartChip System as the product of choice for genomic analysis in high-growth markets such as next-generation sequencing.  We launched the 5,184 (5K) nanowell system in August 2010, and have subsequently added additional products to broaden the platform's applicability.  We have enhanced our distribution capability to Europe, Japan and China and grown our Management team, Board of Directors and Scientific Advisory Board to sustain our growth.  We anticipate that 2011 will be a year of strong growth and broader commercial adoption for the company, with new products, applications and additional customers."

RevenueRevenue for the fourth quarter ended December 31, 2010, grew to $712,000 compared to $190,000 for the fourth quarter ended December 31, 2009.  Revenue for the 12 months ended December 31, 2010, grew to $2.2 million compared to $379,000 for the 12 months ended December 31, 2009.  The majority of the revenue was from sales of a combination of one or more of WaferGen's SmartChip Systems, SmartChip Panels (disposable gene chips) and/or SmartChip Gene Expression Profiling Services.

The 2010 revenue growth is primarily the result of favorable market acceptance of the Company's SmartChip Real-Time PCR System, launched in August 2010.  By the end of 2010, WaferGen had a total of 27 customers and/or collaborators, primarily leading academic institutions, that have purchased or used SmartChip products and/or services in their research projects.  The company sold 9 SmartChip Systems to customers in the United States, Europe and the Far East.

Net Income/LossWaferGen reported a net loss of $3.1 million, or $(0.08) per share (basic and diluted), for the fourth quarter of 2010 compared to a net loss of $3.0 million or $(0.10) per share (basic and diluted), for the same period in 2009.  The company reported a net loss of $12.1 million, or $(0.35) per share (basic and diluted), for the year ended December 31, 2010, compared to a net loss of $10.6 million, or $(0.39) per share (basic and diluted), from 2009.

The net loss for the three months and year ended December 31, 2010 increased primarily due to higher operating expenses associated with the commercialization of the SmartChip System.  Operating expenses were $4.0 million for the three months ended December 31, 2010 compared to $3.1 million in the same period of 2009; and were $13.9 million for 2010 compared to $10.1 million for 2009.

Net loss for the three and 12 months ended December 31, 2010, was impacted by warrant derivative revaluations.  Net gains from warrant derivative revaluations for the three months ended December 31, 2010, were $541,000, compared to a net loss of $64,000 for the three months ended December 31, 2009; and a net gain for the 12 months ended December 31, 2010, of $555,000 compared to a net loss of $564,000 for 2009.  These non-cash losses and gains are attributed to revaluations of outstanding warrants and result primarily from a fluctuation in the company's stock price in the period – an increase in company stock price results in losses and vice versa.

Operating Expenses For the three months ended December 31, 2010, research and development expenses decreased to $1.6 million as compared to $1.7 million for the three months ended December 31, 2009.  For the 12 months ended December 31, 2010, research and development expenses increased to $6.7 million, as compared to $5.1 million for 2009.  The increase in research and development expenses for the 12 months ended December 31, 2010, occurred primarily from expenses associated with the development of SmartChip products and services.

For the three months ended December 31, 2010, sales and marketing expenses increased to $694,000, as compared to $149,000 for the three months ended December 31, 2009.  For the 12 months ended December 31, 2010, sales and marketing expenses increased to $2.1 million, as compared to $601,000 for 2009.  The increase in sales and marketing expenses in both the fourth quarter and 12 months ended December 31, 2010, resulted primarily from additional staff and promotional activities in conjunction with the commercialization and sales of SmartChip Systems and services.

For the three months ended December 31, 2010, general and administrative expenses increased to $1.6 million, as compared to $1.2 million for the three months ended December 31, 2009.  For the 12 months ended December 31, 2010, general and administrative expenses increased to $5.1 million as compared to $4.4 million for 2009.  General and administrative expenses increased due primarily to additional staff and consulting expenses.

AssetsWaferGen ended 2010 with $2.2 million in unrestricted cash and cash equivalents, and $4.3 million of total current assets.  These figures do not include $5 million in proceeds from the financing with a strategic investor, Malaysian Technology Development Corporation Sdn. Bhd. that was announced in December 2010 and funded in 2011.  The company ended 2009 with approximately $6.4 million in total current assets, including $6.0 million in cash and cash equivalents.

About WaferGen and the SmartChip Real-Time PCR SystemWaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for genomic analysis for the life science and pharmaceutical industries.  The company currently offers the breakthrough SmartChip Real-Time PCR System, the next-generation Real-Time PCR system for discovery and validation of biomarkers, or gene expression patterns, on a single platform. The company believes that the SmartChip System is ideal for researchers seeking to confirm discoveries made with the growing use of next-generation sequencing.  In addition, the high throughput capabilities of the SmartChip System enable researchers to extend their research across large panels of genes, and hundreds of samples, at a very reasonable cost.

Combined with next-generation chemistry and optimized assays being developed by WaferGen under the guidance of David Gelfand, Ph.D., Chief Scientific Officer and one of the pioneers of PCR, the SmartChip system is designed to provide accurate, highly sensitive and high-throughput gene expression profiling capabilities to researchers, clinicians and pharmaceutical companies.

In addition, the company offers an innovative fee-based service for gene-expression profiling using the SmartChip System.  For additional information, please see

Forward-Looking Statements This press release contains certain "forward-looking statements".  Such statements include statements relating to the expected benefits and advantages of the SmartChip service for gene-expression research, the expected benefits and advantages of the SmartChip technology to other applications, the expected throughput levels of the SmartChip Real-Time PCR System, the expected growth in the adoption of the company's products in 2011, the expected introduction of new products and applications by the company in 2011, the expected addition of new customers in 2011, and other statements relating to future events or to the company's future financial performance and are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words.

Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company.  Actual results may differ materially from the expectations contained in the forward-looking statements.  Factors that may cause such differences include the risks that: (i) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) the company will need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (iii) the company's proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively.  More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2009 and the most recent Form 10-Q.  Investors and security holders are urged to read these documents free of charge on the SEC's web site at  The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.Contact:WaferGen510-651-4450Don Huffman, CFOdon.huffman@wafergen.comJoyce Strandjoyce.strand@wafergen.comConsolidated Balance SheetsDecember 31, 2010December 31, 2009AssetsCurrent assets:  Cash and cash equivalents$


5,953,639  Restricted cash100,651––  Accounts receivable778,769258,855  Inventories, net1,024,25039,970  Prepaid expenses and other current assets176,259138,712Total current assets4,289,8706,391,176Property and equipment, net1,191,840441,996Other assets334,85557,982  Total assets$


6,891,154Liabilities and Stockholders' Equity (Deficit)Current liabilities:  Accounts payable$


1,240,397  Accrued rent98,05710,493  Accrued payroll268,686241,586  Accrued severance pay18,260371,596  Accrued vacation153,155117,619  Deferred revenue25,000––  Warranty reserve36,850––  Accrued other expenses293,590157,699  Current portion of long-term debt419,38421,663Total current liabilities2,509,8432,161,053Long-term debt, net of current portion1,589,4688,852Put option derivative liability194,088—Warrant derivative liability2,240,9622,778,191Redeemable convertible preference shares in subsidiary3,337,4763,290,994Commitments and contingencies——Stockholders' equity (deficit):  Preferred Stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding——  Common Stock: $0.001 par value; 300,000,000 shares authorized; 41,175,464 and 33,387,857 shares issued and outstanding at December 31, 2010 and December 31, 200941,17533,388  Additional paid-in capital38,881,07529,017,578  Deficit accumulated during the development stage(43,265,399)(30,462,283)  Accumulated other comprehensive income287,87763,381  Total stockholders' equity (deficit)(4,055,272)(1,347,936)$


6,891,154Consolidated Statements of OperationsPeriod FromThree Months EndedYear EndedOctober 22, 2002(Inception) toDecember 31,December 31,December 31,20102009201020092010Revenue






3,462,796Cost of revenue278,27056,380862,066263,0411,467,006  Gross margin434,099133,3771,305,223116,3321,995,790Operating expenses:  Sales and marketing694,340149,0042,072,611601,2454,854,870  Research and development1,628,2621,700,4586,714,3405,142,08322,552,813  General and administrative1,645,0701,213,0655,097,7974,383,08216,871,033Total operating expenses3,967,6723,062,52713,884,74810,126,41044,278,716Operating loss(3,533,573)(2,929,150)(12,579,525)(10,010,078)(42,257,926)Other income and (expenses):  Interest income2,4644,70117,53614,493277,394  Interest expense(29,375)(2,375)(31,329)(9,570)(352,783)  Unrealized gain (loss) on fair value of put option, net(35,906)––88,567—88,567  Unrealized gain (loss) on fair value of warrants, net540,618(63,739)555,144(564,122)(8,978)  Miscellaneous expense(2,077)(16,727)(137,774)(51,211)(267,489)Total other income and (expenses)475,724(78,140)492,144(610,410)(263,289)Net loss before provision for income taxes(3,057,849)(3,007,290)(12,087,381)(10,620,488)(42,546,215)Provision for income taxes—————Net loss(3,057,849)(3,007,290)(12,087,381)(10,620,488)(42,546,215)Cumulative effect of reclassification of warrants————368,627Accretion on Redeemable Convertible Preference Shares in subsidiary associated with premium(63,484)(63,070)(286,948)(178,162)(503,026)Accretion on Redeemable Convertible Preference Shares in subsidiary associated with beneficial conversion feature––––(428,787)—(428,787)Accretion on Series B Preferred Stock————(155,998)   Net loss attributable to common stockholders






(43,265,399)Net loss per share – basic and diluted





(0.39)Shares used to compute net loss per share - basic and diluted40,967,78030,321,72737,070,40627,378,293

SOURCE WaferGen Biosystems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WaferGen Appoints Industry Leader Dr. Timothy J. Triche to Board of Directors
2. WaferGen to Present at 13th Annual BIO CEO and Investor Conference
3. WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board
4. WaferGen to Present at OneMedForum San Francisco 2011
5. WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System
6. WaferGen Announces $7 Million Capital Raise -- $5 Million Equity Private Placement Agreement Signed, and $2 Million Credit Facility Closed
7. WaferGen Reports Second Quarter 2010 Financial Results
8. WaferGen to Introduce New Service for Gene-Expression Profiling Using the SmartChip(TM) Real-Time PCR System
9. WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System
10. Cellceutix Reports Production of Its Anti-Cancer Drug Kevetrin™ Has Begun
11. Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
Post Your Comments:
(Date:12/1/2015)... BOSTON , December 1, 2015 Russia ... phase III clinical trials. 70% of new drugs registered in ... trials in Russia . --> Russia has ... trials. 70% of new drugs registered in Europe ... . --> Russia has always been ...
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. ... treatment of chronic pain, announced today that the company will ... be held December 1-3 at the Luxe Sunset Boulevard Hotel ... Traversa , CEO of Relmada Therapeutics, will present on Thursday, ... Time). . Please register at least 10 ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center ... and is the only hospital in the region providing what is known as ... transcatheter pacing patients were revealed recently at a medical conference and published in ...
(Date:12/1/2015)... MD (PRWEB) , ... December 01, 2015 , ... ... salmon identification tests to continue the expansion of the company’s growing product line ... – for Chinook (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... Health Center of Excellence (BHCOE) today announced that the organization has awarded Education ... San Francisco, with a Distinguished Award. The award celebrates exceptional special needs providers ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... for Effective Post-Affiliation Integration ,” addresses a main “pain point” for merging or ... anticipated results, once a deal is signed. This quick-read guidance suggests that ...
Breaking Medicine News(10 mins):